Medtronic, Genzyme Team Up To Develop Cellular Cardiac Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme expects to complete enrollment of its Phase II myoblast cardiac therapy trial by late 2006. While the clinical trials are ongoing, the company will outfit Medtronic’s TransAccess catheter for myoblast delivery. CBER likely would review the combination product.